Meaningful survival benefit for single lung transplantation in idiopathic pulmonary fibrosis patients over 65 years of age
Peter Riddell, Jana Kleinerová, Donna Eaton, David Healy, Hossein Javadpour, Jim McCarthy, Lars Nölke, Karen Redmond, Jim Egan
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that results in progressive respiratory failure and death. Antifibrotic therapy has been shown to slow disease progression [1, 2]. For many patients [3], lung transplantation is the only intervention recognised to provide significant survival benefit [4]. IPF commonly affects older patients, with a median age at diagnosis of 66 years old [5]. Without transplantation, the median survival from diagnosis is 2–4 years [5]. However, registry data indicates impaired outcomes following lung transplantation for older patients 6]. These data have prompted many centres in Europe to avoid offering transplantation to older IPF patients. This study demonstrates a clinically meaningful survival benefit of lung transplantation for IPF patients aged ≥65 years <http://bit.ly/39pwH2h>